CCEL CRYO CELL INTERNATIONAL INC
Services-Misc Health & Allied Services, NEC · NYSE · SEC CIK 862692 · Fiscal year ends 11/30
Financial factors as of 2026-08-31 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY-2.0%
TTM net income YoY-310.8%
TTM EPS YoY-380.0%
Revenue 3-yr CAGR-0.1%
Net income 3-yr CAGR—
Margins
Gross margin78.5%
Operating margin0.6%
Net margin-6.2%
FCF margin14.9%
EBITDA margin3.4%
Returns
ROE—
ROA-3.1%
ROIC (approx.)—
Asset turnover0.50x
Leverage & solvency
Liabilities / assets126.3%
Debt / equity—
Current ratio0.86x
Interest coverage0.10x
Cash quality & payout
Operating cash flow / net income-2.53x
Accruals ratio-10.9%
Payout ratio—
Capex / revenue0.9%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-11-30 | FY20242024-11-30 |
|---|---|---|
| Income statement | ||
| Revenue | $31.57M | $31.99M |
| Cost of revenue | $7.38M | $7.95M |
| Gross profit | $24.19M | $24.04M |
| R&D expense | $376,263 | $1.24M |
| SG&A expense | $18.22M | $18.52M |
| Operating income | $482,394 | $3.48M |
| Interest expense | $2.07M | $1.86M |
| Pretax income | -$2.34M | $2.80M |
| Income tax | $92,232 | $2.40M |
| Net income | -$2.43M | $402,095 |
| EBITDA | $1.47M | $4.17M |
| EPS (basic) | -0.30 | 0.05 |
| EPS (diluted) | -0.30 | 0.05 |
| Dividends declared per share | — | 0.25 |
| Weighted avg. shares (diluted) | 8.07M | 8.21M |
| Balance sheet | ||
| Cash & equivalents | $319,031 | $560,960 |
| Short-term investments | $2.98M | $2.94M |
| Receivables | $6.85M | $7.31M |
| Inventory | $408,794 | $657,703 |
| Current assets | $11.76M | $12.55M |
| PP&E, net | $21.03M | $21.89M |
| Goodwill | $1.94M | $1.94M |
| Intangibles | $863,074 | $921,254 |
| Total assets | $61.73M | $64.68M |
| Current liabilities | $19.79M | $21.60M |
| Long-term debt | $8.35M | $8.48M |
| Total debt | $8.35M | $8.48M |
| Total liabilities | $80.33M | $77.89M |
| Shareholders' equity | -$18.61M | -$13.22M |
| Net debt | $8.03M | $7.92M |
| Shares outstanding | 8.06M | 8.08M |
| Cash flow statement | ||
| Operating cash flow | $5.48M | $6.01M |
| Capital expenditure | $230,475 | $2.40M |
| Free cash flow | $5.25M | $3.61M |
| Investing cash flow | -$975,332 | -$4.88M |
| Financing cash flow | -$4.75M | -$979,118 |
| Depreciation & amortization | $985,242 | $693,847 |
| Stock-based compensation | $417,101 | $781,128 |
| Dividends paid | $3.23M | $2.02M |
| Share buybacks | $169,502 | $1.42M |
Free plan shows the latest 2 periods; Pro shows all 16 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.